HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study-Reference-Cited by-同舟云学术

HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study

Published:2020-08-20 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

van Balen Peter,Jedema Inge,van Loenen Marleen M.,de Boer Renate,van Egmond H. M.,Hagedoorn Renate S.,Hoogstaten Conny,Veld Sabrina A. J.,Hageman Lois,van Liempt P. A. G.,Zwaginga Jaap-Jan,Meij Pauline,Veelken H.,Falkenburg J. H. F.,Heemskerk Mirjam H. M.

Funder

ZonMw

KWF Kankerbestrijding

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference40 articles.

1. Allo-reactive T cells for the treatment of hematological malignancies;Falkenburg;Mol Oncol,2015

2. Autosomal minor histocompatibility antigens: how genetic variants create diversity in immune targets;Griffioen;Front Immunol,2016

3. LB-ARHGDIB-1R as a novel minor histocompatibility antigen for therapeutic application;Pont;Haematologica,2015

4. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells;Norde;Blood,2009

5. Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation;Hobo;Biol Blood Marrow Transplant,2013

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TCR targeting hematopoiesis to cure leukemia;Blood;2024-09-05

2. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation;Blood;2024-09-05

3. Validating human induced pluripotent stem cell-specific quality control tests for the release of an intermediate drug product in a Good Manufacturing Practice quality system;Cytotherapy;2024-09

4. Production of donor-derived cytotoxic T lymphocytes with potent anti-leukemia activity for adoptive immunotherapy in high-risk pediatric patients given haploidentical hematopoietic stem cell transplantation;Cytotherapy;2024-08

5. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies;Biomarker Research;2024-07-29